APO Research
Talk to an analyst

APO RESEARCH · REPORT

DPP-4 Inhibitors for Type 2 Diabetes Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 2032

29 December 2025106 pages

Choose your research edition.

Industry ResearchDPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global DPP-4 Inhibitors for Type 2 Diabetes Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment include Novartis, Merck, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Mitsubishi Tanabe Pharma, LG Life Sciences and Dong-A Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The DPP-4 Inhibitors for Type 2 Diabetes Treatment market size, estimates, and forecasts are presented in terms of sales volume (M Pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to DPP-4 Inhibitors for Type 2 Diabetes Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Company

Novartis

Merck

Eli Lilly and Company

AstraZeneca

Takeda Pharmaceutical

Sanwa Kagaku Kenkyusho

Mitsubishi Tanabe Pharma

LG Life Sciences

Dong-A Pharmaceuticals

Bristol-Myers Squibb

Boehringer Ingelheim

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Alogliptin

Linagliptin

Saxagliptin

Vildagliptin

Sitagliptin

Others

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application

Hospitals and Clinics

Offline Retail Pharmacy

E-commerce and Internet Medical Care

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DPP-4 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPP-4 Inhibitors for Type 2 Diabetes Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Alogliptin Table 2. Major Company of Linagliptin Table 3. Major Company of Saxagliptin Table 4. Major Company of Vildagliptin Table 5. Major Company of Sitagliptin Table 6. Major Company of Others Table 7. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 9. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type (2021-2026) Table 10. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 11. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type (2021-2026) Table 12. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2026) & (US$/K Pcs) Table 13. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 14. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type (2027-2032) Table 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (US$ Million) Table 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type (2027-2032) Table 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Type (2027-2032) & (US$/K Pcs) Table 18. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 19. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 20. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 21. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 23. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 25. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 27. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 28. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends Table 29. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers Table 30. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges Table 31. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints Table 32. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company (2021-2026) Table 34. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Company (2021-2026) & (M Pcs) Table 35. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Company (2021-2026) Table 36. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Price by Company (2021-2026) & (US$/K Pcs) Table 37. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Major Company Production Sites and Headquarters Table 39. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company, Product Type & Application Table 40. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs) Table 45. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Region (2021-2026) Table 46. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (US$ Million) Table 47. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Region (2021-2026) Table 48. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 49. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (M Pcs) Table 50. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Region (2027-2032) Table 51. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (US$ Million) Table 52. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Region (2027-2032) Table 53. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2027-2032) Table 54. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 56. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application (2021-2026) Table 57. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 58. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application (2021-2026) Table 59. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2026) & (US$/K Pcs) Table 60. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 61. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application (2027-2032) Table 62. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (US$ Million) Table 63. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application (2027-2032) Table 64. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Application (2027-2032) & (US$/K Pcs) Table 65. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 66. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 67. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 68. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 70. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 72. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 74. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 78. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 79. Novartis Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 83. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 84. Merck Recent Development Table 85. Eli Lilly and Company Company Information Table 86. Eli Lilly and Company Business Overview Table 87. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 88. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 89. Eli Lilly and Company Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 93. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Takeda Pharmaceutical Company Information Table 96. Takeda Pharmaceutical Business Overview Table 97. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 98. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 99. Takeda Pharmaceutical Recent Development Table 100. Sanwa Kagaku Kenkyusho Company Information Table 101. Sanwa Kagaku Kenkyusho Business Overview Table 102. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 103. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 104. Sanwa Kagaku Kenkyusho Recent Development Table 105. Mitsubishi Tanabe Pharma Company Information Table 106. Mitsubishi Tanabe Pharma Business Overview Table 107. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 108. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 109. Mitsubishi Tanabe Pharma Recent Development Table 110. LG Life Sciences Company Information Table 111. LG Life Sciences Business Overview Table 112. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 113. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 114. LG Life Sciences Recent Development Table 115. Dong-A Pharmaceuticals Company Information Table 116. Dong-A Pharmaceuticals Business Overview Table 117. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 118. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 119. Dong-A Pharmaceuticals Recent Development Table 120. Bristol-Myers Squibb Company Information Table 121. Bristol-Myers Squibb Business Overview Table 122. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 123. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 124. Bristol-Myers Squibb Recent Development Table 125. Boehringer Ingelheim Company Information Table 126. Boehringer Ingelheim Business Overview Table 127. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 128. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 129. Boehringer Ingelheim Recent Development Table 130. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 131. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 132. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 133. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 134. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 135. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 137. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 138. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 140. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 141. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 142. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 143. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 144. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 145. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 147. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 148. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 150. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 151. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 152. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 153. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 154. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 155. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 156. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 157. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 158. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 159. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 160. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 161. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 162. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 163. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 164. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 165. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 167. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 168. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 170. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 171. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 172. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 173. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 174. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 175. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 177. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 178. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 180. Key Raw Materials Table 181. Raw Materials Key Suppliers Table 182. DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors List Table 183. DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers List Table 184. Research Programs/Design for This Report Table 185. Authors List of This Report Table 186. Secondary Sources Table 187. Primary Sources List of Figures Figure 1. DPP-4 Inhibitors for Type 2 Diabetes Treatment Image Figure 2. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs) Figure 5. Alogliptin Image Figure 6. Global Alogliptin Sales YoY Growth (2021-2032) & (M Pcs) Figure 7. Linagliptin Image Figure 8. Global Linagliptin Sales YoY Growth (2021-2032) & (M Pcs) Figure 9. Saxagliptin Image Figure 10. Global Saxagliptin Sales YoY Growth (2021-2032) & (M Pcs) Figure 11. Vildagliptin Image Figure 12. Global Vildagliptin Sales YoY Growth (2021-2032) & (M Pcs) Figure 13. Sitagliptin Image Figure 14. Global Sitagliptin Sales YoY Growth (2021-2032) & (M Pcs) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (M Pcs) Figure 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Type 2025 VS 2032 Figure 19. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 20. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 21. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 22. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 25. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 26. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 DPP-4 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospitals and Clinics Image Figure 32. Global Hospitals and Clinics Sales YoY Growth (2021-2032) & (M Pcs) Figure 33. Offline Retail Pharmacy Image Figure 34. Global Offline Retail Pharmacy Sales YoY Growth (2021-2032) & (M Pcs) Figure 35. E-commerce and Internet Medical Care Image Figure 36. Global E-commerce and Internet Medical Care Sales YoY Growth (2021-2032) & (M Pcs) Figure 37. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Application 2025 VS 2032 Figure 39. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 40. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 41. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 42. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 45. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 46. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 49. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 50. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 54. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 58. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 62. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 66. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Saxagliptin
  • Vildagliptin
  • Sitagliptin
  • Others
Applications
  • Hospitals and Clinics
  • Offline Retail Pharmacy
  • E-commerce and Internet Medical Care
Companies covered
  • Novartis
  • Merck
  • Eli Lilly and Company
  • AstraZeneca
  • Takeda Pharmaceutical
  • Sanwa Kagaku Kenkyusho
  • Mitsubishi Tanabe Pharma
  • LG Life Sciences
  • Dong-A Pharmaceuticals
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Type
  6. 1.3.1 Alogliptin
  7. 1.3.2 Linagliptin
  8. 1.3.3 Saxagliptin
  9. 1.3.4 Vildagliptin
  10. 1.3.5 Sitagliptin
  11. 1.3.6 Others
  12. 1.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  13. 1.4.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends
  2. 2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
  3. 2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
  4. 2.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2026)
  2. 3.2 Global Top Players by DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2026)
  3. 3.3 Global Top Players by DPP-4 Inhibitors for Type 2 Diabetes Treatment Price (2021-2026)
  4. 3.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Major Company Production Sites & Headquarters
  6. 3.6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company, Product Type & Application
  7. 3.7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 DPP-4 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 DPP-4 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3
4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Regional Status and Outlook
  1. 4.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Historic Market Size by Region
  3. 4.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales in Value by Region (2021-2026)
  5. 4.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Forecasted Market Size by Region
  7. 4.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales in Value by Region (2027-2032)
  9. 4.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 DPP-4 Inhibitors for Type 2 Diabetes Treatment by Application
  1. 5.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Application
  2. 5.1.1 Hospitals and Clinics
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 E-commerce and Internet Medical Care
  5. 5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 5.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Eli Lilly and Company
  14. 6.3.1 Eli Lilly and Company Company Information
  15. 6.3.2 Eli Lilly and Company Business Overview
  16. 6.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  18. 6.3.5 Eli Lilly and Company Recent Developments
  19. 6.4 AstraZeneca
  20. 6.4.1 AstraZeneca Company Information
  21. 6.4.2 AstraZeneca Business Overview
  22. 6.4.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  24. 6.4.5 AstraZeneca Recent Developments
  25. 6.5 Takeda Pharmaceutical
  26. 6.5.1 Takeda Pharmaceutical Company Information
  27. 6.5.2 Takeda Pharmaceutical Business Overview
  28. 6.5.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  30. 6.5.5 Takeda Pharmaceutical Recent Developments
  31. 6.6 Sanwa Kagaku Kenkyusho
  32. 6.6.1 Sanwa Kagaku Kenkyusho Company Information
  33. 6.6.2 Sanwa Kagaku Kenkyusho Business Overview
  34. 6.6.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  36. 6.6.5 Sanwa Kagaku Kenkyusho Recent Developments
  37. 6.7 Mitsubishi Tanabe Pharma
  38. 6.7.1 Mitsubishi Tanabe Pharma Company Information
  39. 6.7.2 Mitsubishi Tanabe Pharma Business Overview
  40. 6.7.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  42. 6.7.5 Mitsubishi Tanabe Pharma Recent Developments
  43. 6.8 LG Life Sciences
  44. 6.8.1 LG Life Sciences Company Information
  45. 6.8.2 LG Life Sciences Business Overview
  46. 6.8.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  48. 6.8.5 LG Life Sciences Recent Developments
  49. 6.9 Dong-A Pharmaceuticals
  50. 6.9.1 Dong-A Pharmaceuticals Company Information
  51. 6.9.2 Dong-A Pharmaceuticals Business Overview
  52. 6.9.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  54. 6.9.5 Dong-A Pharmaceuticals Recent Developments
  55. 6.10 Bristol-Myers Squibb
  56. 6.10.1 Bristol-Myers Squibb Company Information
  57. 6.10.2 Bristol-Myers Squibb Business Overview
  58. 6.10.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  60. 6.10.5 Bristol-Myers Squibb Recent Developments
  61. 6.11 Boehringer Ingelheim
  62. 6.11.1 Boehringer Ingelheim Company Information
  63. 6.11.2 Boehringer Ingelheim Business Overview
  64. 6.11.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  66. 6.11.5 Boehringer Ingelheim Recent Developments
7 North America by Country
  1. 7.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 7.1.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 7.1.3 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 7.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 7.2.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 7.2.3 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 8.1.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 8.1.3 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 8.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 8.2.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 8.2.3 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 9.1.1 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 9.2.1 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 10.1.1 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 10.1.3 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 10.2 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 10.2.1 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 10.2.3 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 11.1.1 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 11.2.1 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
  2. 12.1.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
  7. 12.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
  10. 12.2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst